HighTower Advisors LLC Has $494,000 Stock Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

HighTower Advisors LLC raised its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 64.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,101 shares of the company’s stock after purchasing an additional 2,774 shares during the quarter. HighTower Advisors LLC owned approximately 0.18% of Invesco Biotechnology & Genome ETF worth $494,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Invesco Biotechnology & Genome ETF in the second quarter valued at approximately $26,000. UMB Bank n.a. bought a new position in Invesco Biotechnology & Genome ETF during the second quarter worth $31,000. Howe & Rusling Inc. acquired a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at $31,000. Carnegie Investment Counsel bought a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at about $204,000. Finally, Creative Financial Designs Inc. ADV lifted its stake in shares of Invesco Biotechnology & Genome ETF by 5.6% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock worth $393,000 after buying an additional 299 shares during the last quarter.

Invesco Biotechnology & Genome ETF Price Performance

PBE opened at $67.22 on Friday. The company has a market capitalization of $271.57 million, a PE ratio of 17.12 and a beta of 0.88. The business has a fifty day simple moving average of $69.19 and a 200 day simple moving average of $68.55. Invesco Biotechnology & Genome ETF has a 1 year low of $59.32 and a 1 year high of $72.84.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.